Bone morphogenetic proteins and the polycystic ovary syndrome

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Van Houten, E Leonie A F ^a   Laven, Joop S E ^a   Louwers, Yvonne V ^a   McLuskey, Anke ^a   Themmen, Axel P N ^a   Visser, Jenny A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Assay; BMPs; Marker; PCOS

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; OSTEOGENIC PROTEIN 1;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOASSAY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84876805749     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-32     Document Type: Article

References (31)

1. Polycystic ovary syndrome. Franks S, N Engl J Med 1995 333 853 861 10.1056/NEJM199509283331307 7651477
2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Hum Reprod 2004 19 41 47 14688154
3. Abdominal adiposity and the polycystic ovary syndrome. Escobar-Morreale HF, San Millan JL, TEM 2007 18 266 272 17693095
4. Polycystic ovary syndrome: evidence for a primary disorder of ovarian steroidogenesis. Franks S, Gharani N, Gilling-Smith C, J Steroid Biochem Mol Biol 1999 69 269 272 10.1016/S0960-0760(99)00044-8 10419001
5. Androgen circle of polycystic ovary syndrome. Homburg R, Hum Reprod 2009 24 1548 1555 10.1093/humrep/dep049 19279033
6. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Blank SK, McCartney CR, Marshall JC, Hum Reprod Update 2006 12 351 361 10.1093/humupd/dml017 16670102
7. Follicular dynamics in the polycystic ovary syndrome. Franks S, Mason H, Willis D, Mol Cell Endocrinol 2000 163 49 52 10.1016/S0303-7207(99)00239-7 10963873
8. The spatiotemporal expression pattern of the bone morphogenetic protein family in rat ovary cell types during the estrous cycle. Erickson GF, Shimasaki S, Reprod Biol Endocrinol 2003 1 9 10.1186/1477-7827-1-9 12741959
9. TGF-beta superfamily members and ovarian follicle development. Knight PG, Glister C, Reproduction (Cambridge, England) 2006 132 191 206 10.1530/rep.1.01074
10. The bone morphogenetic protein system in mammalian reproduction. Shimasaki S, Moore RK, Otsuka F, Erickson GF, Endocr Rev 2004 25 72 101 10.1210/er.2003-0007 14769828
11. Oocyte-expressed TGF-beta superfamily members in female fertility. Elvin JA, Yan C, Matzuk MM, Mol Cell Endocrinol 2000 159 1 5 10.1016/S0303-7207(99) 00185-9 10687846
12. Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen AP, Grootegoed JA, Endocrinology 1995 136 4951 4962 10.1210/en.136.11.4951 7588229
13. Expression of bone morphogenetic protein2 (BMP2), BMP4 and BMP receptors in the bovine ovary but absence of effects of BMP2 and BMP4 during IVM on bovine oocyte nuclear maturation and subsequent embryo development. Fatehi AN, van den Hurk R, Colenbrander B, Daemen AJ, van Tol HT, Monteiro RM, Roelen BA, Bevers MM, Theriogenology 2005 63 872 889 10.1016/j.theriogenology.2004.05.013 15629804
14. BMP system expression in GCs from polycystic ovary syndrome women and the in vitro effects of BMP4, BMP6, and BMP7 on GC steroidogenesis. Khalaf M, Morera J, Bourret A, Reznik Y, Denoual C, Herlicoviez M, Mittre H, Benhaim A, Eur J Endocrinol 2013 168 437 444 10.1530/EJE-12-0891 23243014
15. Expression of morphogenic genes in mature ovarian and testicular tissues: potential stem-cell niche markers and patterning factors. von Schalburg KR, McCarthy SP, Rise ML, Hutson JC, Davidson WS, Koop BF, Mol Reprod Dev 2006 73 142 152 10.1002/mrd.20359 16224774
16. Anti-Mullerian hormone: a new marker for ovarian function. Visser JA, de Jong FH, Laven JS, Themmen AP, Reproduction (Cambridge, England) 2006 131 1 9 10.1530/rep.1.00529
17. Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Cook CL, Siow Y, Brenner AG, Fallat ME, Fertil Steril 2002 77 141 146 10.1016/S0015-0282(01)02944-2 11779604
18. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC, J Clin Endocrinol Metab 2004 89 318 323 10.1210/jc.2003-030932 14715867
19. Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, Mason H, J Clin Endocrinol Metab 2007 92 240 245 17062765
20. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC, J Clin Endocrinol Metab 1998 83 2361 2365 10.1210/jc.83.7.2361 9661609
21. Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. van Santbrink EJ, Hop WC, Fauser BC, Fertil Steril 1997 67 452 458 10.1016/S0015-0282(97)80068-4 9091329
22. A functional anti-mullerian hormone gene polymorphism is associated with follicle number and androgen levels in polycystic ovary syndrome patients. Kevenaar ME, Laven JS, Fong SL, Uitterlinden AG, de Jong FH, Themmen AP, Visser JA, J Clin Endocrinol Metab 2008 93 1310 1316 10.1210/jc.2007-2205 18230658
23. Serum anti-Mullerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome. Lie Fong S, Schipper I, de Jong FH, Themmen AP, Visser JA, Laven JS, Fertil Steril 2011 96 459 463 10.1016/j.fertnstert.2011.05.084 21719005
24. Association of serum bone morphogenetic protein 4 levels with obesity and metabolic syndrome in non-diabetic individuals. Son JW, Kim MK, Park YM, Baek KH, Yoo SJ, Song KH, Son HS, Yoon KH, Lee WC, Cha BY, Endocr J 2011 58 39 46 10.1507/endocrj.K10E-248 21186333
25. Growth factor release following femoral nailing. Giannoudis PV, Pountos I, Morley J, Perry S, Tarkin HI, Pape HC, Bone 2008 42 751 757 10.1016/j.bone.2007.12.219 18243089
26. Oocyte-somatic cell interactions during follicle development in mammals. Gilchrist RB, Ritter LJ, Armstrong DT, Anim Reprod Sci 2004 82-83 431 446 23395359
27. Oocyte-expressed genes affecting ovulation rate. McNatty KP, Smith P, Moore LG, Reader K, Lun S, Hanrahan JP, Groome NP, Laitinen M, Ritvos O, Juengel JL, Mol Cell Endocrinol 2005 234 57 66 10.1016/j.mce.2004.08.013 15836953
28. Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis. Park MC, Park YB, Lee SK, Scand J Rheumatol 2008 37 200 204 10.1080/03009740701774941 18465455
29. Increased myocardial collagen turnover in patients with progressive cardiac conduction disease. Bozkaya YT, Aydin HH, Celik HA, Kayikcioglu M, Payzin S, Kultursay H, Aydin M, Yesil M, Can LH, Hasdemir C, Pacing Clin Electrophysiol 2008 31 1284 1290 10.1111/j.1540-8159.2008.01179.x 18811809
30. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy. Wendling D, Cedoz JP, Racadot E, Joint Bone Spine 2008 75 559 562 10.1016/j.jbspin.2008.01.026 18674944
31. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome. Eldar-Geva T, Spitz IM, Groome NP, Margalioth EJ, Homburg R, Hum Reprod 2001 16 2552 2556 10.1093/humrep/16.12.2552 11726573